Filing Flows › Tela Bio (TELA) › Q2 2026
Tela Bio (TELA) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 11, 2026
Tela Bio (TELA) reported revenue of $19.3M for the second quarter 2026 (Q2 2026), -4% from a year earlier and +1% from the quarter before. Operating margin was -48.1%, net loss $11.3M (58.4% of revenue).
Tela Bio, Q2 2026: revenue $19.3M (-4% year over year), operating margin -48.1%, net loss $11.3M, operating cash flow −$9.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $19.3M | +1% | -4% |
| Operating profit | −$9.3M | — | — |
| Net earnings | −$11.3M | — | — |
| Operating cash flow | −$9.4M | — | — |
What changed
Revenue was $19.3M in Q2 2026, down 4% year over year and up 1% from the previous quarter.
Gross margin was 72.3%, up 2.4 points from Q2 2025. Operating costs exceeded revenue by $9.3M, an operating margin of -48.1%. Operating expenses grew 0% against a revenue fall of 4%. The fastest-growing cost line was Research & development (+24%). The quarter ended with a net loss of $11.3M, narrower than the previous quarter's $12.3M loss.
Operating cash flow was −$9.4M. Non-cash charges added back $171K of depreciation and $613K of share-based compensation. Working capital and other items added $1.1M. Capital expenditures of $59K exceeded it, leaving free cash flow of −$9.4M.
Questions
What was Tela Bio's revenue in the second quarter 2026?
Tela Bio (TELA) reported revenue of $19.3M for the second quarter 2026 (Q2 2026), -4% from a year earlier and +1% from the quarter before.
Was Tela Bio profitable in the second quarter 2026?
Operating loss was $9.3M (-48.1% of revenue) and net loss $11.3M.
Source: Tela Bio 10-Q on SEC EDGAR.